Delivery Order SPE2DB20D3103-SPE2DB26FL4P3
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a ceiling value of $1,718.48. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. The contract is expected to be completed by November 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Envarsus XR 4 mg tablets in a quantity of 100 units, with a ceiling value of $1,711.95. This firm fixed-price delivery order is scheduled for ultimate completion by October 20, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Envarsus XR 1 mg tablets in a quantity of 100 units. This competitively awarded, non-set-aside contract carries a ceiling value of $1,718.48 with firm fixed pricing and is scheduled for completion by September 11, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Envarsus XR 4 mg tablets (100-count units) with a ceiling value of $1,804.13. This firm fixed-price delivery order is scheduled for completion by November 21, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting the contractor's demonstrated...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Envarsus XR 4 mg tablets (100 count) with a contract value of $6,847.80. This competitively awarded, non-set-aside delivery order is classified as firm fixed price and will be completed by October 6, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen Drug Corp's substantial...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Envarsus XR 4 mg tablets (100-count) with a ceiling value of $1,711.95 and a firm fixed price structure. The contract represents a non-set-aside, competitively awarded delivery order with an ultimate completion date of September 24, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $5,135.85 to AmerisourceBergen Drug Corp for the supply of Envarsus XR 4 mg tablets (100-count units) on August 22, 2025, with an ultimate completion date of September 15, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Envarsus XR 4 mg tablets (100-count packages) with a contract ceiling value of $1,711.95. This firm fixed-price delivery order, which has an ultimate completion date of October 16, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was made through open competition with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Envarsus XR 1 mg tablets (30-count units) valued at $1,035.60. This non-competitive delivery order, which will be completed by June 24, 2025, represents a firm fixed-price transaction issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contractor, headquartered in Conshohocken, Pennsylvania, will perform this delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Envarsus XR 1 mg tablets (30-count packaging) under a firm fixed-price contract with a ceiling value of $1,165.05. The delivery order, classified as a non-set-aside competitive award, is scheduled for completion by September 9, 2025, with performance and delivery to occur at AmerisourceBergen's distribution facility in Conshohocken, Pennsylvania. This delivery order...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB26FL4P3Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Envarsus XR 4 mg tablets (100 count) with a ceiling value of $5,135.82. This firm fixed-price, competitively awarded delivery order is scheduled for completion by November 21, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's existing pharmaceutical supply relationships with DLA and does not utilize a set-aside designation. This delivery order falls under AmerisourceBergen's broader pharmaceutical distribution activities supporting the Department of Defense medical supply chain. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen maintains an Indefinite Delivery Contract with DLA Troop Support Medical valued at $999,999,999 through December 2026, which serves as the overarching vehicle enabling the company to supply pharmaceutical products and medical supplies to military healthcare systems globally. The current award for Envarsus XR—a tacrolimus formulation used in transplant immunosuppression—exemplifies the company's role in delivering specialized medications across multiple therapeutic domains to support Department of Defense and veteran healthcare requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.1k | 10/30/25 |